Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma.

Wu D, Xu J, Yu G, Zhang B, Wang H, Wang C, Ru G, Sun A, Shen L, Wei Q.

Hepatogastroenterology. 2013 Jan-Feb;60(121):99-106. doi: 10.5754/hge12415.

PMID:
23419663
[PubMed - indexed for MEDLINE]
2.

Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.

Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL.

Med Oncol. 2012 Jun;29(2):933-40. doi: 10.1007/s12032-011-9850-y. Epub 2011 Feb 13.

PMID:
21318736
[PubMed - indexed for MEDLINE]
3.

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10715-20. Epub 2004 Jul 2.

PMID:
15235125
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z.

Mod Pathol. 2011 Jul;24(7):899-907. doi: 10.1038/modpathol.2011.47. Epub 2011 Apr 1.

PMID:
21460800
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study.

Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA, Kowalski LP, Graner E.

Oral Oncol. 2004 Aug;40(7):688-96.

PMID:
15172638
[PubMed - indexed for MEDLINE]
6.

High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy.

Orita H, Coulter J, Tully E, Abe M, Montgomery E, Alvarez H, Sato K, Hino O, Kajiyama Y, Tsurumaru M, Gabrielson E.

Cancer Biol Ther. 2010 Sep 15;10(6):549-54. doi: 10.4161/cbt.10.6.12727. Epub 2010 Sep 21.

PMID:
20657182
[PubMed - indexed for MEDLINE]
Free Article
7.

Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients.

Alo' PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U.

Cancer. 1996 Feb 1;77(3):474-82.

PMID:
8630954
[PubMed - indexed for MEDLINE]
8.

Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings.

Silva SD, Perez DE, Nishimoto IN, Alves FA, Pinto CA, Kowalski LP, Graner E.

Oral Dis. 2008 May;14(4):376-82. doi: 10.1111/j.1601-0825.2007.01395.x.

PMID:
18410580
[PubMed - indexed for MEDLINE]
9.

Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma.

Nemoto T, Terashima S, Kogure M, Hoshino Y, Kusakabe T, Suzuki T, Gotoh M.

Pathobiology. 2001;69(6):297-303.

PMID:
12324706
[PubMed - indexed for MEDLINE]
10.

Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas.

Takahiro T, Shinichi K, Toshimitsu S.

Clin Cancer Res. 2003 Jun;9(6):2204-12.

PMID:
12796387
[PubMed - indexed for MEDLINE]
Free Article
11.

Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.

Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN.

Tumori. 2005 Nov-Dec;91(6):513-21.

PMID:
16457151
[PubMed - indexed for MEDLINE]
12.

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.

Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA.

BMC Cancer. 2009 Jan 7;9:6. doi: 10.1186/1471-2407-9-6.

PMID:
19128465
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.

Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC, Böhle A.

Int J Cancer. 2002 Dec 10;102(5):514-8.

PMID:
12432555
[PubMed - indexed for MEDLINE]
14.
15.

Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study.

Schena M, La Rovere E, Solerio D, Bustreo S, Barone C, Daniele L, Buffoni L, Bironzo P, Sapino A, Gasparri G, Ciuffreda L, Ricardi U.

Tumori. 2012 Jul-Aug;98(4):451-7. doi: 10.1700/1146.12639.

PMID:
23052161
[PubMed - indexed for MEDLINE]
16.

Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N.

Clin Cancer Res. 1999 Sep;5(9):2464-9.

PMID:
10499620
[PubMed - indexed for MEDLINE]
Free Article
17.

[Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma].

Wu HM, Liu YH, Lin F, Xu FP, Luo DL, Zhang F, Zhuang HG, Luo XL, Wu WL, Lin XT.

Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):296-9. Chinese.

PMID:
21756821
[PubMed - indexed for MEDLINE]
18.

Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.

Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M.

J Urol. 2008 Sep;180(3):1137-40. doi: 10.1016/j.juro.2008.04.135. Epub 2008 Jul 18.

PMID:
18639282
[PubMed - indexed for MEDLINE]
19.

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G.

Mod Pathol. 2007 Jan;20(1):120-9. Epub 2006 Nov 24.

PMID:
17143264
[PubMed - indexed for MEDLINE]
Free Article
20.

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.

Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43.

PMID:
14734462
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk